Seropositivity for human T-lymphotropic virus types I and II among donors at the Municipal Blood Bank of Caracas and associated risk factors;Seropositividad al virus linfotrópico de células T humanas tipos I y II en donantes del Banco Municipal de Sangre de Caracas y factores de riesgo asociados

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 13, Issue 2-3, 2003, Pages 117-123

  León, Graciela ^a   Quirós, Ana M ^a   López, José L ^a   Hung, Meilyn ^a   Díaz, Ana M ^a   Goncalves, Juvic ^a   Da Costa, Osiris ^a   Hernández, Teodoro ^a   Chirinos, Merlin ^a   Gómez, Rafael ^a  

^a Banco Metropolitano de Sangre del Distrito Capital   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

BLOOD; MONITORING; RISK FACTOR; VIRAL DISEASE;

ARTICLE; BLOOD BANK; BLOOD DONOR; BREAST FEEDING; COMPARATIVE STUDY; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HEALTH STATUS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INFORMATION PROCESSING; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PREVALENCE; RISK FACTOR; SERODIAGNOSIS; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

VENEZUELA;

EID: 0037304348     PISSN: 10204989     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1020-49892003000200012     Document Type: Article

References (40)

1. Bangham Ch. Human T cell leukemia virus type I and neurological disease. Curr Opin Neurol 1993;3:773-778.
2. Couroucé AM, Pillonnel J, Saura Ch. Screening of blood donations for HTLV I/II. Trans Med Rev 1999;13:267-274.
3. Tokudome S, Tokunaga O, Shimamoto Y, et al. Incidence of adult T cell leukemia/lymphoma among human T-lymphotropic virus type I carriers in Saga, Japan. Cancer Res 1989;49:226-228.
4. Gessain A, Barin F, Vernant J, Gout O, Maurs L, Celender A, et al. Antibodies to human T lymphotropic virus type I in patients with tropical spastic paraparesis. Lancet 1985;2: 407-410.
5. Clark JW, Robert-Guroff M, Ikehara O, Hezam E, Blattner W. Human T cell leukemia lymphoma virus type I and adult T cell leukemia lymphoma in Okinawa. Cancer Res 1985;45:2849-2852.
6. Hjelle B. Human T cell leukemia lymphoma viruses. Life, cycle, pathogenicity, epidemiology and diagnosis. Arch Pathol Lab Med 1991; 115:440-450.
7. Wiktor S, Piot P, Mann J, Nzilambi N, Francis H, Vercauteren G, et al. Human T cell lymphotropic virus type I (HTLV I) among female prostitutes in Kinshasa, Zaire. J Infect Dis 1990;161:1073-1077.
8. Delaporte E, Dupont A, Peeters M, Josse R, Merlin M, Schrijvers D, et al. Epidemiology of HTLV I in Gabon (Western Equatorial Africa). Int J Cancer 1988;42:687-689.
9. Meytes D, Schochat B, Lee H, Nadel G, Sidi Y, Cerney M, et al. A serological and molecular survey for HTLV II infection in a high-risk Middle Eastern group. Lancet 1990;336:1533-1537.
10. Achivon A, Pinhas-Hamiel O, Doll L. Spastic paraparesis associated with human T lymphotropic virus type I: a clinical, serological and genomic study in Iranian-born Mashadi jews. Ann Neurol 1993;34:670-675.
11. Lee H, Swanson P, Shorty V, Zack J, Rosenblatt J, Chen I. High rate of HTLV II infection in seropositive IV drug abusers from New Orleans. Science 1989;244:471-475.
12. Fukushima Y, Takahashi H, Hall W, Nakasone T, Nakata S, Song P, et al. Extraordinary high rate of HTLV type II seropositivity in intravenous drug abusers in South Vietnam. AIDS Res Human Retroviruses 1995;11:637-644.
13. Feigenbaum F, Fang C, Sandler S. Human T lymphotropic virus type II in Panamanian Guaymi Indians. Transfusion 1994;34:158-161.
14. Goubow P, Desmyter J, Ghesquiere J, Busaka K. HTLV II among pigmies. [letter]. Nature 1992;359:201.
15. Maloney E, Biggar E, Neel J, Taylor M, Hahn B, Shaw G, et al. Endemic human T cell lymphotropic virus type II infection among isolated Brazilian Amerindians. J Infect Dis 1992; 166:100.
16. Echeverría G, León-Ponte M, Gallo D, Bianco N. Assessment HTLV assays in HTLV II endemically infected Amerindian population. [Abstract]. Trabajo presentado en la VIII Conferencia Anual de Retrovirus Humanos, Atlanta, Estados Unidos de América, mayo de 1993.
17. Rios M, Khabbaz R, Laflan J, Hall W, Kessler D, Bianco C. Transmission of human T cell lymphotropic virus (HTLV) type II by transfusion of HTLV I screened blood products. J Infec Dis 1994,170:206-210.
18. Sullivan M, Williams A, Fang Ch, Grandinetti T, Poiesz B, Ehrlich G, et al. y The American Red Cross HTLV I/II Collaborative Study Group. Transmission of human T lymphotropic virus types I and II by blood transfusion. A retrospective study of recipients of blood components (1983 through 1989). Arch Int Med 1991;151:2043-2048.
19. Gout O, Baulac M, Gessain A, Semah F, Saal F, Périès J, et al. Rapid development of myelopathy alter HTLV I infection acquired by transfusion during cardiac transplantation. N Eng J Med 1990;322:383-388.
20. Vrielink H, Zaaijer H, Reesink H. The clinical relevance of HTLV type I and II in transfusion medicine. Trans Med Rev 1997;11:173-179.
21. Vrielink H, Zaaijer H, Cuyper H, van der Poel C, Woerdeman M, Lilie P, et al. Evaluation of a new HTLV I/II polymerase chain reaction. Vox Sang 1997;72:144-147.
22. Barun K, Srinivasan A. Multiple primer pairs for the detection of HTLV I infection by PCR. Nucleic Acids Res 1989;17:2142.
23. Tuke P, Luton P, Garson J. Differential diagnosis of HTLV I and HTLV II infections by restriction enzyme analysis of nested PCR products. J Vir Meth 1992;40:163-174.
24. Seiki, Hattori S, Hirayama Y, Yoshida M. Human adult T cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci. USA 1983;80:3618-3622.
25. Shimothono K, Takahashi Y, Shimizu N, Gojobori T, Golde D, Chen I, et al. Complete nucleotide sequence of an infectious clone of human T cell leukemia virus type II: an open reading frame for the protease gene. Proc Natl Acad Sci USA 1985;82:3101-3105.
26. Hassard T. Understanding biostatistics. St. Louis, MO: Mosby Year Book; 1991.
27. Vengelen-Tyler V. Technical Manual AABB. 13th edition. Bethesda, Maryland: AAAB Press; 1999.
28. Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984;46:245-253.
29. Williams L, Blumer S, Schalla W, Robinson P, Handsfield J, Fehd R, et al. Laboratory performance in HTLV I/II analysis. Transfusion 2000;40:1514-1521.
30. Human T lymphotropic virus type I screening in volunteer blood donors, United States. 1989. MMWR 1990;39:915-924.
31. Couroucé A, Pillonel J, Lemaire J. Seroepidemiology of HTLV I/II in universal screening of blood donation in France. AIDS 1993;7:841-847.
32. Mannella E, Micelli M, Di Lorenzo A. Prevalenza della infezioni da HTLV I e II in donatori di sangue. Giornal Ital AIDS 1993; 4:219-223.
33. Zaaijer H, Cuypers H, Wit D, Lelie P. Results of one year screening of donors in the Netherlands for human T lymphotropic virus (HTLV) type I: significance of western blot patterns for confirmation of HTLV infection. Transfusion 1994;34:877-880.
34. Christiansen CB. Experience with one year of blood donor screening for HTLV I/II in Denmark. [abstract]. J AIDS Res Hum Retroviruses 1995;10:251.
35. Centers for Disease Control and Prevention and the USPHS Working Group. Guidelines for counseling persons infected with human T lymphotropic virus type I (HTLV I) and type II (HTLV II). Ann Int Med 1993;118:448-454.
36. Vallejo A, García-Saíz A. HTLV II subtype b among injecting drug users in Spain. Vox Sang 1994;67:81-82.
37. Coste J, Lemare J, Couroucé A, the Retroviral Study Group of the French Society of Blood Transfusion. Human T lymphotropic virus (HTLV) types I and II: seroprevalence among intravenous drug users in continental France. AIDS 1993;7:440-441.
38. León G, Hernández T, García L, Maio A, Quirós A, Gamboa M. Marcadores serológicos para hepatitis B en donantes venezolanos.¿Qué significan? Sangre 1998;43:385-391.
39. Kajiyama W, Kashiwagi S, Ikematsu H, Hayashi J, Nomura H, Okochi K. Intrafamilial transmission of adult T cell leukemia virus. J Infect Dis 1986;154:851-857.
40. León G, Hernández T, Quirós A, Maio A, García L. Cómo reducir la prevalencia de donantes de sangre VIH positivos. Invest Clin 1998;3339:307-321.